LAM-002A

Phase 2Small molecule

OOrphAI Therapeutics

LAM-002A is one of 90 small molecule programs targeting Frontotemporal Dementia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Frontotemporal DementiaActive, not recruiting

LymphomaActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Frontotemporal DementiaPreclinical

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Norvir

AbbVie

Preclinical

1 3

LAM-002A

OOrphAI Therapeutics

Phase 2

1 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Completed·OOrphAI Therapeutics·Phase 1·NCT02594384·62 enrolled

Frontotemporal Dementia1 trial

An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)

No longer available·OOrphAI Therapeutics··NCT05483322

Amyotrophic Lateral Sclerosis1 trial

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

Completed·OOrphAI Therapeutics·Phase 2·NCT05163886·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LAM-002A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LAM-002A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LAM-002A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OrphAI Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOrphAI Therapeutics

LAM-002A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma1 trial

Frontotemporal Dementia1 trial

Amyotrophic Lateral Sclerosis1 trial

References

Drug Info

Quick Facts

Related News